search

Active clinical trials for "Head and Neck Neoplasms"

Results 1361-1370 of 1835

Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin...

Drug/Agent Toxicity by Tissue/OrganHead and Neck Cancer2 more

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating side effects of treatment in patients receiving radiation therapy and cisplatin for advanced head and neck cancer.

Completed3 enrollment criteria

Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer

Head and Neck Cancer

RATIONALE: The use of dentures and dental implants may help maintain chewing and speaking ability following surgery to remove tumors in the mouth. PURPOSE: Phase II trial to study the effectiveness of dentures and dental implants in maintaining the ability to chew and speak in patients undergoing surgery for mouth cancer.

Completed38 enrollment criteria

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer...

Head and Neck CancerOral Complications1 more

RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.

Completed70 enrollment criteria

P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head...

Advanced Head and Neck Cancer

The objectives of this study are to investigate the efficacy and safety of rAd-p53 gene combined with radio- and chemo-therapy vs. radio- and chemo- therapy only in treatment of unresectable, locally advanced head and neck cancer. This is a phase 2, open labeled, and active-controlled study.

Unknown status14 enrollment criteria

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated...

NeoplasmsLung Neoplasms23 more

Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.

Terminated13 enrollment criteria

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary...

Salivary Gland TumorsHead and Neck Cancer

This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.

Unknown status20 enrollment criteria

Oncogeriatric Intervention and Follow-up at Home

NeoplasmsGeriatric Assessment7 more

The study is a randomized study of patients living in four municipalities in Eastern Jutland. After geriatric assessment half of the patients will be offered a tailor-made intervention in their homes. The follow-up will last for at least 90 days and include treatment of the patients' multimorbidity, e.g. of dehydration, anaemia, infections, and malnutrition. The other half of the patients, the results of the assessment and recommendations will be given to the patients and their general practitioner. The primary efficacy variables are accomplishment of planned cancer treatment, reduction of complications and admissions to hospital and increased quality of life,. If geriatric assessment and a tailor-made follow-up result in a better quality of life with less complications and admissions the offer may be extended to a longer period, younger age groups and other cancer diagnoses.

Unknown status7 enrollment criteria

A Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced...

Locally Advanced Head and Neck Cancer

To compare efficacy and toxicity between hypofractionated dose escalated VMAT versus conventional concurrent chemoradiation in locally advanced head and neck cancer

Unknown status15 enrollment criteria

PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer...

Head and Neck Fibrosis

Objectives: This is a feasibility study in preparation for the main multicentre randomised trial, which is anticipated to have two arms: Arm A: the current best standard of care [rehabilitation exercises] Arm B: the current best standard of care [rehabilitation exercises] + the experimental intervention In this feasibility trial the following aspects will be evaluated: Recruitment rates [that is also willingness to be randomised] Feasibility of providing the experimental intervention at the NHS study sites Retention rate/drop out rate Feasibility and acceptability of (i) proposed primary outcome [patient-centred], (ii) a range of additional patient-centred and clinician-centred outcomes Standard deviation of the proposed primary outcome so to inform sample size calculation of the main trial. Safety/toxicity of the study medication. Type of trial: Multicentre, parallel group, randomised controlled trial in 50 patients with radiotherapy-induced fibrosis of the head and neck. Trial design and methods: Participants over the age of 18, with radiotherapy-induced fibrosis of the head and neck will be given information about the trial and invited to participate. 50 participants who consent will be recruited and randomised to either: Treatment with pentoxifylline 400 mg tablets twice a day [total 800mg/day] + 500IU tocopherol acetate solution twice a day [total 1000 IU/day] in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months or Best standard of care [a structured programme of rehabilitation exercises] for 6 months. Randomisation will be carried out online Trial duration per subject: 6 months Estimated total trial duration: 56 months Planned trial sites: Multi-site Total number of subjects planned: 50 participants Main inclusion/exclusion criteria: Inclusion Criteria: Subjects aged ≥18 years Previous history of Head & Neck Cancer Previous radiotherapy to the Head & Neck - minimum 50 Gy completed at least 12 months before screening visit Cancer-free for a minimum of 12 months after completion of radiotherapy. Diagnosis of radiotherapy-induced fibrosis of the head and neck: trismus and/or dysphagia Exclusion Criteria: History of primary cancer resection and/or reconstructive surgery to anatomical areas involved in swallowing and/or chewing. Concomitant presence of other disorders that may cause pharyngeal/oral fibrosis Known hypersensitivity to pentoxifylline or tocopherol (vitamin E). History of acute porphyrias or haemorrhagic disorders Active/ongoing hypotension Diabetes Pregnancy Subjects with osteoradionecrosis Breastfeeding mothers Subjects with a MIO <12mm Statistical methodology and analysis: Analysis of this feasibility trial will be mainly descriptive, measuring recruitment rate, acceptance of randomisation, attrition from treatment and trial, and completion rates for the outcome measures (to gauge acceptability and appropriateness).

Unknown status25 enrollment criteria

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody(SCT200)in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.

Unknown status36 enrollment criteria
1...136137138...184

Need Help? Contact our team!


We'll reach out to this number within 24 hrs